Exicure, Inc. (XCUR)

Market Cap	17.91M -75.1%
Revenue (ttm)	n/a
Net Income	-4.95M
EPS	-0.79
Shares Out	6.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,445
Open	2.760
Previous Close	2.760
Day's Range	2.630 - 2.810
52-Week Range	2.630 - 10.800
Beta	3.62
Analysts	Hold
Price Target	10.00 (+255.87%)
Earnings Date	Jun 26, 2026

About XCUR

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: XCUR
• Website: https://www.exicuretx.com

Analyst Summary

According to one analyst, the rating for XCUR stock is "Hold" and the 12-month stock price target is $10.0.

Price Target

$10.0

(255.87% upside)

Analyst Consensus: Hold